ev3 Inc

ev3 — Investor Presentation (May 2006)

37 slides from ev3's investor presentation, May 5, 2006

  1. Slide 1: Investor Presentation

    THE ENDOVASCULAR COMPANY Investor Presentation Jim Corbett CEO

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain matters discussed today or answers that may be given to questions asked could constitute forward-looking statements that are subject to risks and uncertainties relating to ev3’s future financial or business performance. ev3’s actual results could differ materially from

  3. Slide 3: Who We Are

    Who We Are Catheter-Based Devices for Treating Circulatory and Vascular Disorders fim ry ui Radiologists Cardiologists Neuro’ Radiologists Vascular Surgeons -° Neuro Surgeons Cardiologists

  4. Slide 4: How We Are Organized

    How We Are Organized ev3 2 Operating. CARDIO PERIPHERAL NEURO VASCULAR Divisions DIVISION DIVISION 1 Sales/Marketing ev3 Division INTERNATIONAL

  5. Slide 5: Cardio Peripheral and Neuro Vascular Divisions

    CARDIO PERIPHERAL NEURO VASCULAR DIVISION DIVISION PVD Hemorrhagic Stroke Carotid Artery Disease Ischemic Stroke AMI/SVG Radiologists Neuro Radiologists — : Vascular Surgeons Neuro Surgeons Cardiologists

  6. Slide 6: Extensive Global Presence

    ée ev3'. Extensive Global Presence 0 O EUROPE JAPAN OTHERINT’L TOTAL SALES 109 80 il) 10 209 glut i it operaticis/ 627 31 16 674 Marketing TOTAL 736 111 26 10 883

  7. Slide 7: Accelerating Revenue Growth

    Accelerating Revenue Growth 70%+ CAGR +53% $134 $41.0 $42.2 $33.5 $86 pa $27. $68 j $37 $13 01 02 O03 04 O05 05 05 05 05 06 Q2 i Q3 _e oe ANNUAL QUARTERLY $ MILLIONS

  8. Slide 8: Revenue Growth Across Divisions

    Revenue Growth Across CARDIO PERIPHERAL NEURO $240 $253 19.2 $19.8 } $ $16.8 $123 $137 S70 $168 a2 034 Q2 Q3 04 ai TOTAL U.S. TOTAL INTERNATIONAL: re | pi A 18.3, $17.4 7 9 36 $15.9 $144 $15.6 $14.4 $1 Q2 Q3 04 Qi a2 Q3 4 ai

  9. Slide 9: Revenue Growth Across Products: Cardio Peripheral

    Revenue Growth Across Products STENTS Cardio +84% ) Peripheral $12.1 $13.1 Revenues 9.9 (S MILLIONS) Bo , $7.1 | 2005 | | i206 2 08 @ at | THROMBECTOMY & EMBOLIC PROTECTION © PROCEDURAL SUPPORT & OTHER CP a +21% ¥ +29% " $4.0 $72 $70 $84 soon $32 $29 $3.5 $32 | ‘I = 1 | | a 3 4 ai 02 03 4 a

  10. Slide 10: Revenue Growth Across Products: Neuro

    Revenue Growth Across Products EMBOLIC PRODUCTS +86% $8.1 $74 $8.1 $75 ag Ta oi | } a 038 4 at | a2 © ©03 $8.9 04 NEURO ACCESS & DELIVERY +39% $9.5 1 ‘a Qi Neuro Revenues (S MILLIONS) (2005 2006

  11. Slide 11: Compelling Rationale for Our Strategy

    Compelling Rationale for Our Strategy LARGE & GROWING COMPETITIVE GAP UNDERSERVED/EMERGING MARKETS Batis ; SMALL CAP, * Vascular Disease NARROW x POC LONCRATE $1.6B * Stroke Prevention FOCUS: Je mo © Stroke Treatment Cvs) mm 5 YEAR PRODUCT BREADTH, POTENTIAL GLOBAL PRESENCE STRIKING OCCLUSIVE DISEAS

  12. Slide 12: Organic Innovation to Drive Growth

    Organic Innovation to Drive Growth $ MILLIONS ANNUAL GROWTH $13 o Lar a DIRECT WORLDWIDE SALES FORCE GLOBAL ¥ | _ EXPANSION | - i ¥ R&D New Products DEVELOPMENT & Over of Revenue Growth from NEW PRODUCT FLOW Products Developed in Last 2 Years i New Product Launches Since Q4 ‘04 7)

  13. Slide 13: Large, Growing Addressable Endovascular Device Markets

    Large, Growing Addressable Endovascular Device Markets eV3 CURRENT SHARE- OF ADDRESSABLE MARKETS GROWTH OPPORTUNITY $1.6B Minimally Invasive PERIPHERAL Procedures VASCULAR 2 5 DIVISION Aging Population Improved Outcome ¥ NEURO ji is § VASCULAR Improved Diagnosis i DIVISION 2004

  14. Slide 14: The PVD Market Opportunity

    The PVD Market Opportunity -<7> GROWTH OPPORTUNITY Aging Demographic Expanding Diabetes $1B Population Improved Prevention/ % Diagnosis ¥ Shift from Surgeryto Endovascular Procedures 2004

  15. Slide 15: ev3's Comprehensive Global PVD Product Strategy

    ev3’s Comprehensive Global ©° ev3 PVD Product Strategy Carotid Renais BROADEST STENT/ PTA PORTFOLIO » Protégé © Protégé Rx © Protégé Tapered © Paramount Mini * Protége Bigs © Primus ~ Sailor PTA > Submarine PTA » Protégé Long © Protege EverFlex ~ EverFlex BTK » Amphirion PTA THROMBECTOMY/ EMBOLIC PR

  16. Slide 16: PROTEGE EverFlex Durability

    PROTEGE EverFlex Durability LUMINEXX™ : ZILVER® RELATIVE STENT PERFORMANCE LifeStent NT IN SIMULATED FATIGUE TESTING* ABSOLUTE™ S.M.A.R.T.® Control™ PROTEGE® EverFlex™ 012345 67 8 91011 “Bench testing conducted at ev3. Data on file “Tests stopped with no stent fractures. Test was not intended to be

  17. Slide 17: The Carotid Stenting Opportunity

    The Carotid St Opportunity THE MARKET CAROTID PERIPHERAL VASCULAR DISEASE Undiagnosed/ Existing Not Amenable Surgery to Surgery O16M 1.34M THE ADVANTAGES STANDARD OF CARE: SURGERY STENTING LIMITATIONS BENEFITS Invasive Minimally Invasive Requires General Safe/ nesthesia Well Tolerated Restricted Pat

  18. Slide 18: ev3 Carotid Stenting System

    @, ev3 Carotid Stenting System eve Protégé™ / ProtégéRX Most Reliably Placed Stent DEEP CLINICAL PROCAR CREATE _ CREATE II TRIAL EXPERIENCE | ] Protégé, Protégé, aa RAPID Protégé RX, Protégé RX, Spide! COMMERCIALIZATION protégé Tapered Protégé Tapered Carotid SpideRX SpideRX

  19. Slide 19: Our Carotid Stenting System in Action

    Our Carotid Stenting ee System in Action Cv3.. Internal Carotid Artery gail Protégé Stent Carotid Artery c 4 Guidewire

  20. Slide 20: Clinical Trial Momentum

    Clinical Trial Momentum * Pending FDA Clearance Dr. Rob Safian Dr. Rob Safian Dr. Gary Ansel Dr. Gary Ansel Ye wllaiy ha 747 (Device: 383) (Control: 364) * Sos . éceRX Non Inferiority Compared to SpiderRX+ ProtégéRX — SpiderRX+ ProtégeRX aartwire atal Fitters 6.2% (1 Year: 7.7%) Has aks AT 30 Days A

  21. Slide 21: Critical Limb Ischemia — Global Product Strategy

    Critical Limb Ischemia — Global Product Strategy BROADEST STENT/ THROMBECTOMY/ PTA PORTFOLIO EMBOLIC PROTECTION Tliac * Sailor PTA * Protégé EverFlex SFA > Submarine PTA © SpideRX = Diver CE © X-Sizer Ne, Tibial/Lower Leg © EverFlex BIK: © Amphirion PTA

  22. Slide 22: The Neuro Vascular Market Opportunity

    The Neuro Vascular Market Opportunity GROWTH GROWTH OPPORTUNITY $450M Large Patient Population Improved Detection / Diagnosis Shift from Surgery to ‘ Endovascular Procedures ¥ Improving Device Technology — Emerging Segments 2005 - Ischemic Stroke

  23. Slide 23: Treating Hemorrhagic Stroke

    Treating Hemorrhagic Stroke Broad Portfolio and Unique Solutions

  24. Slide 24: Hemorrhagic Stroke: A Background

    Hemorrhagic Stroke: A Background AVM ANEURYSM

  25. Slide 25: Neuro Product Platform/Pipeline

    Neuro Product Platform/ Pipeline Sapphire © Tetris NXT EMBOLIC COILS me Revie a LIQUID EMBOLICS Onyx AVM Onyx Aneurysm Onyx Aneurysm HDE Submission Q1 ‘06 MICROCATHETERS Echelon UltraFlow J Marathon OCCLUSION BALLOON HyperForm SYSTEM HyperGlide GUIDEWIRES Mirage NEURO STENTS Solo European Availabili

  26. Slide 26: ev3's Nexus Coil

    ev3’s Nexus” Coil ev3 = THE PROBLEM WITH TRADITIONAL COILS INCOMPLETE FILL ° COILCOMPACTION © RE-GROWTH OF ANEURYSM Helical Niti Cana SALADS mast! Easier Deployment “corn Increased Mass (99%+) . Better Wall Contact — DY, Be aan HJ SUCCESSFUL, LONG LASTING SOLUTION

  27. Slide 27: The Nexus Coil Cross Section

    The Nexus” Coil Cross Section

  28. Slide 28: The Nexus Coil Delivery

  29. Slide 29: The Leverage of Multiple Platforms

    The Leverage of Multiple Platforms = DISEASE OVERLAP TECHNOLOGY CORONARY et Peripheral RVScuTaRd 11% ARTERY ZY and Cardio | DISEASE BEES : S Peripheral 3965 115% ; SD ana carsio| VASCULAR .> Peripheral DISEASE | ~) U7 and Neuro PRODUCT, GEOGRAPHIC s PROTECTION EMBOLIC COIL F ; DEVICE STENT GUIDEWIRE

  30. Slide 30: Product Launch Momentum

    Project Launch Momentum eve = NEXUS Accelerating New Product Launch Rate Primus ° Onyx AVM 90% of Totay's 5 Reveniles from Products . Marathon ® Protégé Bigs i Diver CE ‘in Last 2) Years pele Protégé RX Submarine Echelon Amphirion Deep Paramount Mini X-Sizer US SpideRX Protégé Aqwire Tapered Protégé

  31. Slide 31: New Product Flow - 2006

    New Product Flow - 2006 * Pending FDA Clearance Spider ° Nitrex 2003 * Protégé 6Fr. 035 © Aqwire ° Protégé Longs © SpideRX ° Protégé Tapered * Echelon Paramount Mini ° X-Sizer US 2004 * Marathon * Tetris * Sailor * Submarine © Amphirion Deep * Primus * Protégé Biggs * Diver CE * Protégé RX * NEXUS °

  32. Slide 32: Clinical Trial and Submission Progress

    Clinical Trial and Submission Progress Driving Clinical Indications for Commercial Approval and Clinical Data © SPIDER 510(k) Submission ¢ CREATE PMA Submission © CREATE RX © PROCAR 5 10(k) * PROTECT Submission © SIMPLE » PRIMUS Iliac © XAMINE-ST IDE Submission « XTRACT + REMEDIA 2003 2004 2005, ev3

  33. Slide 33: Management Team

    ev3 POSITION President & CEO CFO President, Neuro Division President, Cardio Peripheral Division President, International VP, R&D Cardio Peripheral, Division & CTO VP, Secretary & Chief Legal Officer VP, Human Resources PAST EXPERIENCE Boston Scientific, SciMED, Baxter Empi, Medtronic Boston Scienti

  34. Slide 34: Diversified, Global Revenues

    Diversified, Global Revenues 70)0}s) $134M Revenue NEURO ; CARDIO. -4qoz US? INTL PERIPHERAL 54% 46% 60% BY MARKET SEGMENT BY GEOGRAPHY

  35. Slide 35: Target Operating Model

    rget Operating Model REVENUES GROSS MARGIN OPERATING EXPENSES: SG&A R&D AMORTIZATION GAIN ON SALES OF ASSETS OPERATING MARGIN 2004 100% 54% 119% 45% 11% (17)% (105)% TARGET 100% 65-70% 30% 15% 5% __% 15-20%

  36. Slide 36: Strategies for Sustainable Growth

    Strategies for Sustainable Growth BROADEN TECHNOLOGY PLATFORM GLOBAL EXPANSION IN GEOGRAPHIC MARKETS CONTINUED PRODUCT DEVELOPMENT. AND LAUNCHES

  37. Slide 37: Searchable text section of graphics shown above

    Searchable text section of graphics shown above [LOGO] THE ENDOVASCULAR COMPANY Investor Presentation Jim Corbett CEO Safe Harbor Statement [LOGO] Certain matters discussed today or answers that may be given to questions asked could constitute forward-looking statements that are subject to risks and

ev3 — Investor Presentation (May 2006) on 6ix